Video goggles help VA in amblyopia

Article

A video goggle-based technology may help increase visual acuity (VA) in children with amblyopia.

A video goggle-based technology called Reviview may help increase visual acuity (VA) in children with amblyopia. The technology is based on the principle that any video content can be transformed into a useful treatment tool for amblyopia.

According to co-inventors Ilan Vadai and Yuval Avni, Reviview incorporates brain stimulation technology designed to improve vision via a set of dedicated video goggles. To improve his or her visual acuity, a child wears the goggles to watch 30 to 60 minutes of their favourite animated television shows per day.

Vadai and Avni both have backgrounds in medical device design; Vadi also has a background in video production.

According to Vadai and Avni, in a study of 16 children aged 4 to 8 years who were provided with prototypes of the device, watching 30 to 60 minutes of their favourite animated television shows led to improvements in VA in 88% of the participants. Improvements after 4 weeks ranged from 1 LogMAR line up to 5 LogMAR lines. The average improvement was 2 lines (±1.7 lines) after 4 weeks and 2.6 lines (±1.5 lines) after 8 weeks.

"Adherence is a major problem with amblyopia treatment routines. With our approach, the fun of the treatment and the fast results contribute to the high level of commitment we see among kids and parents to our unique and patented treatment process," Vadai said.

He added that the goggles could be ready for marketing in about 12 months, and the company is looking for funding to finish the product design and conduct further studies.

For more information go to www.visiortech.com.

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.